Published online Apr 19, 2026. doi: 10.5498/wjp.v16.i4.114081
Revised: November 29, 2025
Accepted: January 14, 2026
Published online: April 19, 2026
Processing time: 170 Days and 20.2 Hours
Diabetic macular edema (DME) is a major cause of vision impairment among working-age adults with diabetes. Treatment adherence remains a considerable challenge, with psychological factors potentially playing a crucial role.
To investigate the relationship between depression, anxiety, and treatment ad
A retrospective cohort study was conducted at our hospital January 2021 and August 2025, including 130 patients with DME. Depression and anxiety were assessed using the Patient Health Questionnaire-9 (PHQ-9) and Generalized An
Among 130 patients, 44.6% (n = 58) demonstrated depression symptoms (PHQ-9 ≥ 5), and 37.7% (n = 49) showed anxiety symptoms (GAD-7 ≥ 5). Poor medication adherence (Medication Adherence Report Scale-5 < 17) was observed in 43.1% (n = 56) of patients. Depression severity was significantly associated with low me
Depression and anxiety significantly impact treatment adherence in DME patients. Integrated care approaches addressing both psychological and ophthalmological aspects are essential for optimizing treatment outcomes.
Core Tip: Depression and anxiety are frequent psychiatric comorbidities in patients with diabetic macular edema and play a crucial role in treatment adherence. This retrospective study found that both disorders were strongly associated with poor medication compliance and reduced appointment attendance, ultimately leading to impaired visual outcomes and lower quality of life. Treatment adherence partially mediated the link between depression and vision loss. These findings underscore the need for integrated management strategies that combine psychiatric care with ophthalmological treatment to optimize adherence and improve clinical prognosis in diabetic macular edema.
